- Surrozen Inc (NASDAQ:SRZN) entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413 for retinal diseases.
- SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology.
- It is currently being developed for the treatment of retinal vascular-associated diseases.
- In preclinical models of retinopathy, SZN-413 could potently stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth, and reduce vascular leakage.
- Also See: Surrozen’s Q2 Earnings
- Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop SZN-413 and other Fzd4-specific Wnt-modulating molecules for all purposes, including as a treatment for retinal diseases, for an upfront of $12.5 million.
- Surrozen will also be eligible to receive up to $586.5 million in milestone payments.
- After an initial joint research period, Boehringer Ingelheim will assume all development and commercial responsibilities.
- Price Action: SRZN shares are up 9.40% at $2.36 on the last check Thursday.
Actinium Announces Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit In High-Risk Relapsed Or Refractory Acute Myeloid Leukemia Patients With TP53 Mutations Accepted For Oral Presentation At The European Bone Marrow Transplant Annual…
- The SIERRA results demonstrate Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis- Represents the
